Masitinib
- Generic Name
- Masitinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H30N6OS
- CAS Number
- 790299-79-5
- Unique Ingredient Identifier
- M59NC4E26P
- Background
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
- Associated Conditions
- -
- Associated Therapies
- -
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- AB Science
- Target Recruit Count
- 335
- Registration Number
- NCT00812240
- Locations
- 🇫🇷
Centre Val d'Aurèle, Montpellier, France
🇱🇧Makassed General Hospital Tarik Jadide, Beirut, Lebanon
🇱🇧Hôpital Saint-Georges, Beirut, Lebanon
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- AB Science
- Target Recruit Count
- 353
- Registration Number
- NCT00789633
- Locations
- 🇫🇷
Hôpital André Mignot, Le Chesnay, France
🇷🇴Emergency Clinical Hospital, Constanta, Romania
🇨🇿Oncology Surgery, Kutná Hora, Czechia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath